In April 2014, Apta Biosciences successfully raised £1,850,000 for its synthetic molecule business to continue undergoing validation work with partners for therapeutics.
Apta produces Adaptamers; molecules that have much in common with antibodies, but offer a better performance because of their ease to make and use. Most of us probably don’t think about antibodies too often, but we have a lot to thank them for: our own natural antibodies help us to fight viruses and dangerous bacteria every single day. This is clearly reflected by the market for antibodies and their alternatives, which is deemed to be worth an impressive $60 billion p.a.
Apta Biosciences is headed up by a team of experienced life sciences entrepreneurs. The company was spun-out from Fujitsu in August 2013, where the technology was worked on for more than 10 years.
The round was lead by Ranworth Capital: a UK family office with a life sciences focus.
Where are they now?
Apta Biosciences has sinced raised a further round on SyndicateRoom at an uplift on its previous valuation. More details to follow.
See current opportunities